register

News & Trends - Pharmaceuticals

New treatment for brain cancer more effective than conventional therapy

Health Industry Hub | August 17, 2020 |

Pharma News: A recent study by Monash University has uncovered a potential new drug that may lead to new treatments for common brain cancers.

The study, published in Purinergic Signalling  and led by Neurologist and Research Fellow Dr Mastura Montif from Monash University’s Department of Neuroscience,  demonstrated that a protein (P2X7R) known to enhance tumour growth can be inhibited by using a specific compound drug, currently known only as AZ10606120.  

This drug was more effective than the current conventional chemotherapy, MSD’s Temodal (temozolomide) and its generic forms.

Using both human glioblastoma cells and tumour samples from patients at The Alfred and Royal Melbourne Hospital, the findings give hope for an effective treatment to fight this aggressive cancer.

Gliomas are the most common cancers of the brain, accounting for 80% of all brain tumours. Among these, glioblastoma is the most aggressive form, killing an estimated 225,000 people worldwide per year with patients only surviving for a median of 14-15 months after diagnosis. 

Current treatment options are limited to surgical removal, radiotherapy and chemotherapy, and only prolong survival by several months. Despite advancements in treatment, the prognosis for glioblastoma patients remains bleak. 

Unlike many other cancers, there has been no significant improvements in therapies for glioblastoma in the last 12 years.There is a desperate need for the development of more effective therapies.

“This is very exciting as it brings promise to the potential of this compound AZ10606120 in the treatment of glioblastoma and sheds further light on the role of the protein P2X7R in these tumours,” Dr Montif said 

“Our future endeavours will involve testing in animal models, which will hopefully lead to a human clinical trial.

“Seeing patients diagnosed with this lethal and life changing disease, and most of them being young and their whole life ahead of them, is the reason why I continue to pursue research on glioblastoma. 

“As a clinician and a researcher I feel like we need to do more, and we need to act urgently to prevent more lives being affected.”


News & Trends - Pharmaceuticals

Clinicians unveil Novartis and BMS practice-changing trial results

Clinicians unveil Novartis and BMS practice-changing trial results

Health Industry Hub | June 24, 2024 |

Pharma News: Australia, known for its alarming melanoma rates, witnesses one person diagnosed with the disease every 30 minutes, and […]

More


News & Trends - Pharmaceuticals

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Health Industry Hub | June 24, 2024 |

Pharma News: Heart failure is a significant health concern in Australia, affecting approximately half a million people, with over 67,000 […]

More


News & Trends - MedTech & Diagnostics

Cardiologists mark Australian first with Boston Scientific's intracoronary imaging system

Cardiologists mark Australian first with Boston Scientific’s intracoronary imaging system

Health Industry Hub | June 24, 2024 |

MedTech & Diagnostics News: Percutaneous coronary intervention (PCI) has faced substantial complications and failure rates, despite advances in medical devices […]

More


Leadership & Management

AbbVie New Zealand welcomes new leadership amid global moves

AbbVie New Zealand welcomes new leadership amid global moves

Health Industry Hub | June 24, 2024 |

Leadership & Management: In line with its global talent development plan, AbbVie has announced a significant change in leadership for […]

More


This content is copyright protected. Please subscribe to gain access.